Vyepti and Sumatriptan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vyepti (eptinezumab-jjmr) and Sumatriptan (sumatriptan succinate). Common drug interactions include drug ineffective among females and paraesthesia among males.

The phase IV clinical study analyzes what interactions people have when they take Vyepti and Sumatriptan. It is created by eHealthMe based on reports of 69 people who take the same drugs from the FDA, and is updated regularly.

What is Vyepti?

Vyepti has active ingredients of eptinezumab-jjmr. eHealthMe is studying from 4,897 Vyepti users. Check the latest studies of Vyepti.

What is Sumatriptan?

Sumatriptan has active ingredients of sumatriptan succinate. It is often used in migraine. eHealthMe is studying from 18,159 Sumatriptan users. Check the latest studies of Sumatriptan.



On Jul, 19, 2026

69 people who take Vyepti and Sumatriptan together, and have interactions are studied.

Vyepti and Sumatriptan drug interactions.

What are the common drug interactions of Vyepti and Sumatriptan, by gender? *:

female:

  1. Drug ineffective
  2. Headache (pain in head)
  3. Constipation
  4. Fatigue (feeling of tiredness)
  5. Oropharyngeal pain
  6. Nausea (feeling of having an urge to vomit)
  7. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  8. Throat irritation
  9. Disturbance in attention
  10. Sinusitis (inflammation of sinus)

male:

  1. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  2. Asthenia (weakness)
  3. Change of bowel habit
  4. Drug ineffective
  5. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  6. Visual impairment
  7. Dysgeusia (disorder of the sense of taste)
  8. Erectile dysfunction
  9. Libido decreased (loss of interest in sex)
  10. Nasopharyngitis (inflammation of the nasopharynx)

What are the common drug interactions of Vyepti and Sumatriptan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Vomiting

20-29:

  1. Drug ineffective
  2. Infusion site rash
  3. Nausea (feeling of having an urge to vomit)

30-39:

  1. Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
  2. Throat irritation
  3. Headache (pain in head)
  4. Disturbance in attention
  5. Constipation
  6. Nausea (feeling of having an urge to vomit)
  7. Fatigue (feeling of tiredness)
  8. Oropharyngeal pain
  9. Aura
  10. Confusional state

40-49:

  1. Throat irritation
  2. Fatigue (feeling of tiredness)
  3. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  4. Oropharyngeal pain
  5. Blood pressure increased
  6. Drug ineffective
  7. Nausea (feeling of having an urge to vomit)
  8. Nephrolithiasis (calculi in the kidneys)
  9. Urticaria (rash of round, red welts on the skin that itch intensely)
  10. Cough

50-59:

  1. Drug ineffective
  2. Oropharyngeal pain
  3. Headache (pain in head)
  4. Fatigue (feeling of tiredness)
  5. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  6. Nasopharyngitis (inflammation of the nasopharynx)
  7. Hypersensitivity
  8. Sneezing
  9. Visual impairment
  10. Anxiety

60+:

  1. Headache (pain in head)
  2. Dizziness
  3. Dyspnoea (difficult or laboured respiration)
  4. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  5. Speech disorder
  6. Alopecia (absence of hair from areas of the body)
  7. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  8. Dry eye (lack of adequate tears)
  9. Dry skin
  10. Increased appetite

What are the existing conditions these people have? *

  1. Headache (pain in head): 6 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Vyepti and Sumatriptan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Vyepti and Sumatriptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Vyepti:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Sumatriptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Vyepti and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sumatriptan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on eptinezumab-jjmr and sumatriptan succinate (the active ingredients of Vyepti and Sumatriptan, respectively), and Vyepti and Sumatriptan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: